Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
AstraZeneca
National Cancer Institute (NCI)
AstraZeneca
BioNTech SE
Charles University, Czech Republic
Genmab
Daiichi Sankyo
Karyopharm Therapeutics Inc
Queensland Centre for Gynaecological Cancer
Gustave Roussy, Cancer Campus, Grand Paris
UNICANCER
Hutchmed
University of Virginia